FDA requests additional information on HLB’s new drug, 7month 10day HLB affiliates’ shares plunge
HLB was 7month 10day after the U.S. Food and Drug Administration (FDA) requested additional information on its liver cancer drug, and shares of HLB affiliates hit the daily lower limit during trading. During the same period, news emerged that E-Mart’s target price was 15% lower, Samsung SDS’s target price was raised, and KT&G was assigned a target price of 22ten thousand won amid expectations for an interim dividend.
HLB disclosed that it had been asked by the U.S. Food and Drug Administration (FDA) on 7month 10day to provide additional information related to its liver cancer drug. Immediately after the disclosure, HLB and related affiliate stocks hit the daily lower limit during trading.
On this day (7month 9–10day), some securities firms announced that they had lowered E-Mart’s target price by 15%. The announcement included that weak Starbucks sales had an impact.
It was pointed out that, including leveraged products, trading value related to Samsung Electronics and SK hynix accounts for 83% of the total. This is a figure reflecting the concentration of trading in the market.
Samsung SDS’s target price was raised as its AI data center business became more visible. The related news was reported on 7 month 9 day.
KT&G was assigned a target price of 22ten thousand won as its interim dividend and shareholder return policy attracted attention. This news also emerged on 7 month 9 day.
By stock, disclosures related to new drug development and news of securities firms changing their target prices emerged around the same time, appearing to disperse investor attention.
If additional disclosures or securities firm reports are released, individual stocks are expected to experience significant price fluctuations.